Novel protein kinase signaling associated with platinum resistance in ovarian cancer

Active Project Grant Awarded Last action

Award ID
R01CA256482
Recipient
Awarding agency
Obligated
$5,240,836

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 86% complete
Originally
Funding
  • $4,797,823.00 Federal
  • $443,013.00 Non-federal
Place of performance
Gainesville, FL 32611, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Development of platinum resistance is one of the most important factors contributing to ovarian cancer recurrence and mortality. In our effort to decipher molecular mechanisms underlying platinum resistance, we performed a kinome-wide screening on platinum-resistant SK-OV3 ovarian cancer cell line and identified SRC- related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites (SRMS) as a top platinum resistance regulator. Further analysis of tcga ovarian cancer dataset revealed that patients with high SRMS expression responded poorly to platinum-based therapy and had worse overall survival. Since knockdown of SRMS markedly sensitized P53-deficient ovarian cancer cell lines to platinum while only displayed minor effect on P53-competent cell lines, we reason that SRMS plays a critical role in platinum resistance of P53-deficient ovarian cancer. To glean the mechanistic insight into the role of SRMS in platinum resistance, we showed that SRMS prevents JNK activation, possibly by directly phosphorylating jnks. JNK signaling pathway is well established as an essential mediator for apoptosis triggered by cytotoxic agents; our observation that SRMS is specifically involved in platinum resistance in P53-deficient cells suggests that 1) platinum induces apoptosis in P53-deficient ovarian cancer cells in a JNK signaling pathway-dependent manner because of the defect in P53 signaling pathway-mediated apoptosis; and 2) SRMS-led inhibition of JNK signaling alleviates platinum-induced apoptosis and thereby promotes platinum resistance in P53-deficient cells. P53 is uniformly deficient in high grade serous ovarian cancer (HGSOC). The discovery of SRMS' prominent role in platinum resistance of P53- deficient cells indicates that SRMS can be an ideal therapeutic target against platinum resistance in HGSOC. In our "drug repurposing" screening, we found that PLX4720, a selective inhibitor of B-RAFV600E, can potently inhibit SRMS activity. In this application, we propose 3 specific aims: 1) characterize molecular mechanisms underlying SRMS-conferred platinum resistance; 2) define platinum resistance-relevant events that are governed by SRMS-JNK signaling; and 3) investigate the potential of targeting SRMS to augment efficacy of platinum therapy. The success of this application will uncover molecular mechanism underlying SRMS' role in platinum resistance of ovarian cancer. Importantly, we will evaluate SRMS-targeted strategy to overcome platinum resistance in ovarian cancer.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $443,013 $0
Amendment $443,013 $0
Amendment $420,861 $0
Amendment $0 $0
Amendment $434,151 $0
Amendment $434,151 $0
Amendment $434,152 $0
Amendment $434,152 $0
Amendment $434,152 $0
Amendment $434,152 $0
Amendment $443,013 $0
Original award $443,013 $443,013
Show all 15

Subawards

Subrecipient Amount Awarded
The University Of Texas Health Science Center At San Antonio Dr. Lingtao Jin is an expert in chemo-resistance and has previously identified several key molecules critical for intrinsic drug resistance in lung cancer.… $206,256
The University Of Texas Health Science Center At San Antonio Dr. Lingtao Jin is an expert in chemo-resistance and has previously identified several key molecules critical for intrinsic drug resistance in lung cancer.… $217,076
University Of Texas Health Science Center Of San Antonio $217,076

Quick answers

Who received award R01CA256482?

R01CA256482 was awarded to University Of Florida by National Cancer Institute (National Institutes of Health) on September 1, 2021.

How much is award R01CA256482 worth?

$5,240,836 has been obligated on R01CA256482: $4,797,823 in federal funding and $443,013 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login